Current report, item 1.01

bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">



Washington, DC 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 25, 2021




(Exact Name of Registrant as Specified in its Charter)


(State or Other Jurisdiction of Incorporation)


(Commission  File Number)

1350 Old Bayshore Highway, Suite 400

Burlingame, California 94010

(650) 238-9600


(I.R.S. Employer Identification Number)

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share


The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement

The purchase of shares pursuant to that certain Share Repurchase Agreement by and between Innoviva, Inc. (the “


”) and Glaxo
Group Limited, previously reported on Form 8-K filed with the U.S. Securities and Exchange Commission on May 20, 2021, closed on May 25, 2021 and the shares have been transferred to the Company.


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

Date: May 26, 2021



/s/ Pavel Raifeld

Pavel Raifeld

Chief Executive Officer

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Theravance makes a similar move, sign up!

Other recent filings from the company include the following:

OrbiMed Genesis GP LLC just provided an update on activist position in Theravance - Oct. 19, 2021
James just provided an update on activist position in Theravance - Oct. 18, 2021
Major owner of Theravance just declared 0 ownership of the company. - Oct. 15, 2021
Major owner of Theravance just picked up 1,615,427 shares - Oct. 15, 2021
Theravance's See Remarks just picked up 625 shares - Oct. 14, 2021

Auto Refresh